Sana Biotechnology (NASDAQ:SANA) Earns “Buy” Rating from HC Wainwright

Sana Biotechnology (NASDAQ:SANA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 213.73% from the stock’s current price.

Several other research analysts also recently issued reports on the company. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. Citigroup lifted their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Sana Biotechnology Stock Up 4.1 %

Shares of NASDAQ SANA opened at $2.55 on Wednesday. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $5.19. Sana Biotechnology has a 52 week low of $2.29 and a 52 week high of $12.00. The stock has a market capitalization of $569.34 million, a price-to-earnings ratio of -1.82 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities research analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Richard Mulligan sold 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now owns 2,848,121 shares of the company’s stock, valued at approximately $11,620,333.68. This represents a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 31.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the third quarter worth $29,000. Barclays PLC lifted its position in Sana Biotechnology by 126.6% during the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after buying an additional 178,179 shares during the period. Geode Capital Management LLC boosted its stake in Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after buying an additional 276,055 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in Sana Biotechnology in the 3rd quarter valued at about $45,000. Finally, State Street Corp increased its stake in shares of Sana Biotechnology by 4.2% during the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after acquiring an additional 269,274 shares during the last quarter. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.